{"id":155849,"date":"2026-11-20T17:07:17","date_gmt":"2026-11-20T08:07:17","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4882-20261120-01_wp_general_ir\/"},"modified":"2026-11-20T17:07:17","modified_gmt":"2026-11-20T08:07:17","slug":"4882-20261120-01_wp_general_ir","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261120-01_wp_general_ir\/","title":{"rendered":"Notice of Issuance of the 31st Stock Acquisition Rights (with Exercise Price Adjustment Clause) by Third-Party Allotment and Conclusion of Stock Acquisition Rights Purchase Agreement"},"content":{"rendered":"<p>Issuance of stock acquisition rights by third-party allotment (total 46,000 units, total amount 1,334,000 yen, potential shares 4,600,000 shares) and planned conclusion of a purchase agreement with Macquarie Bank Limited. Exercise price is subject to a 92% adjustment clause with a floor of 56 yen. Funds are intended for research and development and working capital; exercise period runs from 2026-12-09 to 2028-12-08.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4882","jir_company_name":"Perseus Proteomics Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-20","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4882-20261120-01.pdf","jir_short_summary":"Issuance of stock acquisition rights by third-party allotment (total 46,000 units, total amount 1,334,000 yen, potential shares 4,600,000 shares) and planned conclusion of a purchase agreement with Macquarie Bank Limited. Exercise price is subject to a 92% adjustment clause with a floor of 56 yen. Funds are intended for research and development and working capital; exercise period runs from 2026-12-09 to 2028-12-08.","jir_summary":"### Overview of Fundraising and Terms\nThese stock acquisition rights will be allotted to Macquarie Bank Limited by third-party allotment, with a two-year exercise period. The initial exercise price is 102 yen, thereafter adjusted to 92% of the exchange closing price, but if exercises exceed limits or the exchange closing price on the issuance resolution date is lower, a floor price of 56 yen will apply. Fundraising is assumed to be equivalent to 2.2 billion yen, and proceeds will be allocated to research and development and working capital. Transfer restrictions on the allottee, non-exercise periods, and lock-up conditions will also be imposed.\n\n### Outlook and Impact on Capital Policy\nThis fundraising is intended to maximize long-term corporate value and is not expected to have a material impact on earnings forecasts for the fiscal year ending March 2027. The company aims to strengthen its next-generation drug discovery platform through advancement of its drug discovery pipeline, including PPMX-T004, and the introduction of AI hybrid drug discovery. Dilution is expected to be up to 4,600,000 shares (approximately 24.96% dilution assumed), but the inclusion of non-exercise periods is designed to mitigate market impact.","jir_financial_highlights":"Potential shares: 4,600,000 shares (Unknown)\nTotal stock acquisition rights: 46,000 units (Unknown)\nExercise period: 2026-12-09 to 2028-12-08 (Unknown)","jir_category":"","jir_hashtags":"#PerseusProteomics, #StockAcquisitionRights, #Fundraising","jir_key_figures":"Potential shares: 4,600,000 shares\nTotal stock acquisition rights: 46,000 units\nTotal subscription amount: 1,334,000 yen (29 yen per unit)","jir_meta_title":"Perseus Proteomics Inc. \u2014 Notice of Third-Party Allotment of Stock Acquisition Rights | November 2026","jir_meta_description":"Perseus Proteomics Inc. plans to issue the 31st stock acquisition rights by third-party allotment and conclude a purchase agreement with Macquarie Bank Limited. Total 46,000 units; potential 4,600,000 shares; exercise price adjustment clause and non-exercise periods disclosed. Proceeds to be used for drug discovery development and working capital.","jir_og_title":"Perseus Proteomics Inc. \u2014 Notice of Issuance of Stock Acquisition Rights | November 2026","jir_og_description":"Announcement of issuance of stock acquisition rights by third-party allotment and conclusion of a purchase agreement. Details include potential 4,600,000 shares, exercise price adjustment conditions, and non-exercise periods. Funds to be used for drug discovery development and working capital.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60609,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-155849","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notice of Issuance of the 31st Stock Acquisition Rights (with Exercise Price Adjustment Clause) by Third-Party Allotment and Conclusion of Stock Acquisition Rights Purchase Agreement - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261120-01_wp_general_ir\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261120-01_wp_general_ir\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261120-01_wp_general_ir\/\",\"name\":\"Notice of Issuance of the 31st Stock Acquisition Rights (with Exercise Price Adjustment Clause) by Third-Party Allotment and Conclusion of Stock Acquisition Rights Purchase Agreement - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-11-20T08:07:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261120-01_wp_general_ir\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261120-01_wp_general_ir\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261120-01_wp_general_ir\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Notice of Issuance of the 31st Stock Acquisition Rights (with Exercise Price Adjustment Clause) by Third-Party Allotment and Conclusion of Stock Acquisition Rights Purchase Agreement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Notice of Issuance of the 31st Stock Acquisition Rights (with Exercise Price Adjustment Clause) by Third-Party Allotment and Conclusion of Stock Acquisition Rights Purchase Agreement - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261120-01_wp_general_ir\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261120-01_wp_general_ir\/","url":"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261120-01_wp_general_ir\/","name":"Notice of Issuance of the 31st Stock Acquisition Rights (with Exercise Price Adjustment Clause) by Third-Party Allotment and Conclusion of Stock Acquisition Rights Purchase Agreement - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-11-20T08:07:17+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261120-01_wp_general_ir\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261120-01_wp_general_ir\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261120-01_wp_general_ir\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Notice of Issuance of the 31st Stock Acquisition Rights (with Exercise Price Adjustment Clause) by Third-Party Allotment and Conclusion of Stock Acquisition Rights Purchase Agreement"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"60609","title":"PERSEUS PROTEOMICS INC","ticker":"4882"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/155849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=155849"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/155849\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=155849"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=155849"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=155849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}